dextran 40 x x RN dextran 70 x x RN dextrose 10% Glucose RN RN RN May be given in peripheral IV dextrose 20 35% Glucose RN RN RN Must be given via central IV line – dextrose 50% Glucose x RN x diazepam Valium x RN x digoxin Lanoxin x SC, Ra3 x Telemetry monitoring required digoxin Immune FAB Digibind BS BS x dihydroergotamine DHE 45 x RN x Telemetry monitoring required diltiazem Cardizem x SC, Ra3 SC, Ra3 RN titration only allowed for SC diphenhydrAMINE Benadryl x RN x diphtheria antitoxin RN RN RN Only available from the CDC DOBUTamine –critical care Dobutrex x x SC, Ra3* * See link for guidelines on use in Ra3 patients. DOBUTamine Ra3 – Taxotere CH x x DOCEtaxel DOPamine Intropin x x SC Restricted to maintain vascular access (e.g. – dornase-alfa Pulmozyme x Provider x chest tube) only doxapram Dopram SC SC SC DOXOrubicin Adriamycin CH CH CH DOXOrubicin liposomal CH x x – doxycycline Vibramycin RN x x edetate Ca disodium Calcium EDTA RN x RN enalaprilat Vasotec SC, Ra3 SC, Ra3 x For IV push, ensure appropriate BP monitoring
dextran 40 x x RN dextran 70 x x RN dextrose 10% Glucose RN RN RN May be given in peripheral IV dextrose 20 – 35% Glucose RN RN RN Must be given via central IV line dextrose 50% Glucose x RN x diazepam Valium x RN x digoxin Lanoxin x SC, Ra3 x Telemetry monitoring required digoxin Immune FAB Digibind BS BS x dihydroergotamine DHE 45 x RN x diltiazem Cardizem x SC, Ra3 SC, Ra3 Telemetry monitoring required RN titration only allowed for SC diphenhydrAMINE Benadryl x RN x diphtheria antitoxin RN RN RN Only available from the CDC DOBUTamine –critical care DOBUTamine – Ra3 Dobutrex x x SC, Ra3* * See link for guidelines on use in Ra3 patients. DOCEtaxel Taxotere CH x x DOPamine Intropin x x SC dornase-alfa Pulmozyme x Provider x Restricted to maintain vascular access (e.g. – chest tube) only doxapram Dopram SC SC SC DOXOrubicin Adriamycin CH CH CH DOXOrubicin – liposomal CH x x doxycycline Vibramycin RN x x edetate Ca disodium Calcium EDTA RN x RN enalaprilat Vasotec SC, Ra3 SC, Ra3 x For IV push, ensure appropriate BP monitoring
sfgh_infusion_guide_rv_05-5-16_final.docx